Your session is about to expire
← Back to Search
NMS-03305293 for Solid Tumors
Study Summary
This trial is testing a new cancer drug to see if it is safe and works against different types of cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are expected to live for at least 3 more months.You can swallow the study medication capsules without breaking them open or chewing them.You must have already tried certain treatments before joining the study.You have received platinum therapy in the past, but your disease got worse during treatment or it came back within 6 months after finishing platinum therapy as part of your previous treatment plan.You have had a previous type of cancer, except for specific types of cancer that are allowed in this study.You have been diagnosed with advanced/metastatic breast cancer, ovarian cancer, castration-resistant prostate cancer, or pancreatic cancer. The presence of specific gene mutations (BRCA1 and BRCA2) is not necessary for participation, but we will try to include those who have these mutations.If you have HER2 negative breast cancer, you should have received no more than 3 chemotherapy treatments for advanced or spreading cancer. There is no limit on previous hormonal or targeted therapies. You should have received at least one treatment with taxane or anthracycline chemotherapy, unless it was not recommended for you. If your cancer is hormone receptor positive, you should have received at least one treatment with hormonal therapy. If you were treated with a PARP inhibitor before, it is required for you to participate in the study for HER2 negative breast cancer.In the past 6 months, you have had a heart attack, chest pain that comes and goes, surgery to improve blood flow to your heart or limbs, heart failure with symptoms, stroke or mini-stroke, blood clot in your lungs, or blood clot in your legs.You have had up to 4 previous treatments for advanced or spreading ovarian cancer, including at least one treatment involving platinum-based chemotherapy.
- Group 1: Dose Expansion Part - Epithelial Ovarian Cancer
- Group 2: Dose Expansion Part - Pretreated HER 2 Neg. Breast Cancer
- Group 3: Dose Expansion Part - CRPC
- Group 4: Dose Expansion Part - Pancreatic Cancer
- Group 5: Dose Escalation Part
- Group 6: Dose Expansion Part - No Pretreated HER 2 Neg. Breast Cancer
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are partaking in this empirical research?
"Affirmative, according to clinicaltrials.gov this research endeavour is actively searching for subjects. It was first posted on November 25th 2019 and recently amended on March 14th 2022. The study's objective is to include 150 patients from one location into the trial."
Has NMS-03305293 achieved the green light from the FDA?
"Our team at Power assigned a value of 1 to the safety rating for NMS-03305293, as this is an early clinical trial and there is limited data about its efficacy."
Could patients join the experiment at this time?
"Confirmed. According to information published on clinicaltrials.gov, this trial is presently seeking participants who meet eligibility criteria. The trial was initially listed on November 25th 2019 and has been amended as recently as March 14th 2022. This medical study seeks 150 patients from one location for enrolment into the program."
Share this study with friends
Copy Link
Messenger